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AbstrACt
Introduction Non-invasive ventilation (NIV) is 
recommended as first-line therapy in respiratory failure 
of critically ill immunocompromised patients as it can 
decrease intubation and mortality rates as compared 
with standard oxygen. However, its recommendation is 
only conditional. Indeed, the use of NIV in this setting has 
been challenged recently based on results of trials finding 
similar outcomes with or without NIV or even deleterious 
effects of NIV. To date, NIV has been compared with 
standard oxygen but not to high-flow nasal oxygen therapy 
(HFOT) in immunocompromised patients. Several studies 
have found lower mortality rates using HFOT alone than 
when using HFOT with NIV sessions in patients with de 
novo respiratory failure, and even in immunocompromised 
patients. We are hypothesising that HFOT alone is more 
effective than HFOT with NIV sessions and reduces 
mortality of immunocompromised patients with acute 
hypoxemic respiratory failure.
Methods and analysis This study is an investigator-
initiated, multicentre randomised controlled trial comparing 
HFOT alone or with NIV in immunocompromised patients 
admitted to intensive care unit (ICU) for severe acute 
hypoxemic respiratory failure. Around 280 patients will be 
randomised with a 1:1 ratio in two groups. The primary 
outcome is the mortality rate at day 28 after inclusion. 
Secondary outcomes include the rate of intubation in each 
group, length of ICU and hospital stay and mortality up to 
day 180.
Ethics and dissemination The study has been approved 
by the ethics committee and patients will be included 
after informed consent. The results will be submitted for 
publication in peer-reviewed journals.
trial registration number NCT02978300
IntroduCtIon
background and rationale
Acute hypoxemic respiratory failure is the 
leading cause of admission to intensive 
care units (ICUs) in immunocompromised 
patients.1 Intubation and subsequent invasive 
strengths and limitations of this study
 ► This trial is the first to compare high-flow nasal oxy-
gen therapy (HFOT) alone versus HFOT with non-in-
vasive ventilation (NIV) sessions for treatment of 
acute hypoxemic respiratory failure in immunocom-
promised patients admitted to intensive care unit.
 ► The settings of the oxygenation techniques com-
pared have been protocolised based on physio-
logical studies in order to optimise their efficiency 
(improvement in oxygenation, decrease in work of 
breathing, limitation of patient self-inflicted lung 
injury).
 ► The sample size of this trial has been designed to 
have the power to detect a difference in mortality 
rates of patients with severe acute hypoxemic re-
spiratory failure.
 ► The individual study assignments of the patients will 
not be masked. Given the nature of the two strat-
egies under evaluation, a double-blind trial is not 
possible.
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Table 1 Characteristics and outcomes of previous trials comparing non-invasive ventilation to oxygen therapy in 
immunocompromised patients
Authors Year Setting N= Arms Intubation rate (%) In-ICU mortality rate (%)
Antonelli et al 2000 ICU, monocentre 20 O2 70 50
20 NIV 20 20
Hilbert et al 2001 ICU, monocentre 26 O2 77 69
26 NIV 46 38
Lemiale et al 2015 ICU, multicentre 183 O2 45 25
191 NIV 38 21
Squadrone et al 2010 Ward, monocentre 20 O2 40 75*
20 CPAP 10 15*
Frat et al† 2016 ICU, multicentre 30 O2 43 20
26 NIV 65 42
26 HFOT 31 15
Outcomes of patients in the control arm are displayed in italics.
*Hospital mortality (ICU mortality was not indicated in the article).
†Post hoc analysis of a randomised trial.
CPAP, continuous positive airway pressure; HFOT, high-flow nasal oxygen therapy;ICU, intensive care unit; NIV, non-invasive ventilation; O2, 
oxygen therapy.
mechanical ventilation are needed in about two-thirds of 
cases and are associated with particularly high mortality 
reaching 50%–70% of cases.1–3 Therefore, it is crucial 
to assess the best strategy of oxygenation with the aim of 
avoiding the need for intubation in immunocompromised 
patients.
According to a large international cohort study, non-inva-
sive ventilation (NIV) is used in up to 21% of cases in this 
setting.4 It is worth noting that recent European/American 
clinical practice guidelines have recommended NIV as first-
line therapy for management of acute hypoxemic respi-
ratory failure in immunocompromised patients.5 Indeed, 
by pooling all randomised controlled trials, NIV has been 
associated with decreased intubation and mortality rates as 
compared with standard oxygen (table 1).6–9 However, the 
largest randomised controlled trial comparing NIV vs stan-
dard oxygen found no difference in intubation or mortality 
rates and application of NIV was consequently only a condi-
tional recommendation.6
All previous studies have compared NIV to standard 
oxygen and not versus high-flow nasal oxygen therapy 
(HFOT).5 Recently, better outcomes have been reported 
with HFOT than with standard oxygen, and even as 
compared with HFOT with NIV in patients with acute 
hypoxemic respiratory failure.10–12 However, the design 
of these studies (retrospective monocentre or post-hoc) 
excludes any definite conclusion on the best treatment 
option for immunocompromised critically ill.10 11 13 There-
fore, there is an urgent need for a dedicated trial designed 
to compare NIV to HFOT in immunocompromised criti-
cally ill patients taking into account the suggested dele-
terious effects of NIV.10 11 Indeed, NIV may be associated 
with harmful effects in de novo respiratory failure,14 espe-
cially in patients generating strong inspiratory efforts and 
subsequent large tidal volumes due to high transpulmonary 
pressures.15 16 It could be argued that NIV protocol had not 
been protective enough, that is, by applying low levels of 
pressure-support (PS) to avoid large tidal volumes that may 
worsen underlying lung injury,17 by applying high levels of 
positive end-expiratory pressure (PEEP) to promote alve-
olar recruitment as is the case in patients invasively venti-
lated for acute respiratory distress syndrome (ARDS),18 19 
and by applying prolonged sessions of NIV to avoid dere-
cruitment during NIV breakoffs .20 21 Indeed, while most of 
these patients meet the clinical criteria for ARDS,22 optimi-
sation of ventilator settings during NIV could lead to better 
outcomes, as is the case in patients under invasive mechan-
ical ventilation.
objectives
We are aiming to conduct a prospective multicentre 
randomised controlled trial comparing HFOT alone or with 
optimised NIV sessions in immunocompromised patients 
admitted to ICU for acute hypoxemic respiratory failure. 
Our hypothesis is that HFOT alone may reduce mortality 
rate at day 28 as compared with HFOT with NIV, despite 
application of NIV with protective ventilator settings.
Primary objective
To compare the mortality rate at day 28 after inclusion 
between HFOT alone and HFOT with NIV in immuno-
compromised patients admitted to ICU for acute hypox-
emic respiratory failure.
secondary objectives
1. To compare the rates of intubation, and of mortality in 
ICU, in hospital, at day 90 and at day 180 after inclu-
sion between the two strategies.
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2. To compare length of stay in ICU, in hospital and 
number of ventilator-free days (invasive or noninvasive 
mechanical ventilation) within the 28 days following 
inclusion.
3. To compare tolerance between the two strategies.
trial design
The FLORALI-IM study is an investigator-initiated, 
prospective, multicentre, randomised, controlled, open 
trial comparing two strategies of oxygenation using 
HFOT alone or with NIV in immunocompromised 
patients admitted to ICU for acute hypoxemic respiratory 
failure. Patients will be randomly assigned to the HFOT 
alone group or the HFOT with NIV group with a 1:1 ratio.
MEthods
Participants, interventions and outcomes.
study setting
The FLORALI-IM study is taking place in 29 ICUs in 
France and 1 ICU in Italy.
Eligibility criteria
Inclusion criteria
Adult immunocompromised patients admitted to ICU 
for acute hypoxemic respiratory failure are considered 
eligible.
Acute hypoxemic respiratory failure is defined by respi-
ratory rate ≥25 breaths/min, and PaO2/FiO2 ≤300 mm Hg 
while spontaneously breathing under standard oxygen 
with oxygen flow rate of at least 10 L/min, under HFOT, 
or under NIV. For patients under standard oxygen, FiO2 is 
calculated according to the following formula: FiO2=0.21 
+ 0.03 per supplemental litre of oxygen.14
Immunosuppression is defined by one of the following 
criteria: haematological malignancy (active or remitting 
for <5 years), allogenic stem cell transplantation within 
the last 5 years, active solid cancer, leucopenia <1 G/L 
or neutropenia ≤0.5 G/L induced by chemotherapy, solid 
organ transplantation, AIDS, systemic steroids ≥0.5 mg/
kg/day of prednisone equivalent for at least 3 weeks, 
immunosuppressive or immunomodulatory drugs.23
Exclusion criteria
Patients fulfilling one of the following criteria will not be 
included: PaCO2 above 50 mm Hg, patients who could 
strongly benefit from NIV, that is, with underlying chronic 
lung disease, cardiogenic pulmonary oedema or postop-
erative patients; severe shock defined as vasopressor dose 
>0.3 µg/kg/min of norepinephrine-equivalent to main-
tain systolic blood pressure >90 mm Hg or with impaired 
consciousness with a Glasgow coma score ≤12; patients 
with urgent need for intubation, that is, respiratory or 
cardiac arrest, respiratory pauses with loss of conscious-
ness or gasping for air, severe hypoxemia defined as 
SpO2 lower than 90% despite maximal oxygen support; 
patients with do-not-intubate order at time of inclusion; 
or patients with contraindication to NIV according to 
the French consensus conference,24 i.e. patient refusal, 
cardiorespiratory arrest, coma, non-drained pneumo-
thorax, unresolved vomiting, upper airway obstruction, 
haematemesis or severe facial trauma.
Intervention
Patients eligible for inclusion will be informed, asked for 
consent, then randomised within the first 6 hours after 
they meet inclusion criteria, and assigned to one of the 
two following groups: (1) the patients assigned to control 
group will receive HFOT with NIV sessions and (2) the 
patients assigned to interventional group will receive 
HFOT alone.
The purpose of this 6-hour time frame is to avoid the 
possibly harmful delayed initiation of oxygenation strat-
egies. As NIV may be more effective in haematological 
or neutropenic patients,7 randomisation will be stratified 
according to the existence of underlying haematological 
malignancy, leucopenia <1 G/L or neutropenia ≤0.5 G/L 
induced by chemotherapy.
Interventional group: HFOT alone
Immediately after randomisation, patients assigned to 
the interventional group will be continuously treated 
by HFOT (Optiflow or AIRVO2, Fisher & Paykel, Auck-
land, New Zealand) with a flow of 60 L/min and FiO2 
adjusted to obtain adequate oxygenation (SpO2 ≥92%) 
through a heated humidifier (MR 850, Fisher & Paykel, 
Auckland, New Zealand) set to the ‘intubation’ position. 
For patients experiencing HFOT intolerance due to high 
flow levels despite reinsurance, flow will be decreased to 
the maximal tolerated level.
Control group: HFOT with NIV
Immediately after randomisation, NIV will be initi-
ated with a first session of at least 4 hours until clinical 
improvement (assessed by the attending physician) and 
then applied by sessions of at least 1 hour for a minimal 
duration of at least 12 hours a day. NIV will be carried out 
with a ventilator dedicated for NIV (ICU ventilator after 
activation of NIV mode or NIV bi-level ventilator)25 in PS 
ventilatory mode with a minimal PS level of 5 cm H2O 
targeting a tidal volume of 6 mL/kg of predicted body 
weight and avoiding tidal volumes exceeding 8 mL/kg, 
a PEEP level of at least 8 cm H2O, and FiO2 adjusted to 
obtain adequate oxygenation (SpO2 ≥92%). Between NIV 
sessions, HFOT will be delivered as in the interventional 
group. For patients experiencing NIV intolerance despite 
reinsurance, physicians will be encouraged to modify NIV 
settings (level of PS and PEEP, minimising leaks, adjust-
ment of inspiratory trigger and cycling, interface switch) 
to improve NIV tolerance.
Duration of treatment
In the two groups, strategies of oxygenation will be 
applied for a minimal duration of 48 hours. After that, 
continuation of the treatment will be decided according 
to patient respiratory status (figure 1).
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Figure 1 Flowchart of the patients and study design. HFOT, high-flow nasal oxygen therapy; ICU, intensive care unit; NIV, non-
invasive ventilation; PBW, predicted body weight; PEEP, positiveend-expiratory pressure; Vte, expired tidal volume
Criteria for weaning oxygenation strategies
As there is no consensual method of weaning from HFOT 
or NIV, we propose a standardised weaning protocol to 
mitigate differences between centres. From 48 hours after 
inclusion, weaning from both oxygenation strategies will 
be assessed twice a day during the investigator’s round.
In the HFOT alone group, HFOT will be stopped and 
switched to standard oxygen when respiratory rate is <25 
breaths/min and SpO2 ≥92% with FiO2 ≤50% and flow 
≤50 L/min.
In the NIV group, NIV will be stopped first when respi-
ratory rate is <25 breaths/min and SpO2 ≥92% with FiO2 
≤50%, and then HFOT will be stopped and switched to 
standard oxygen as in the HFOT alone group.
At any time after weaning of oxygenation techniques, if 
respiratory rate is ≥25 breaths/min or SpO2 <92% HFOT 
or HFOT with NIV sessions will be resumed according to 
randomisation group.
Prespecified intubation criteria
In order to avoid harmful effects of delayed intubation 
in patients treated with NIV26 27 and HFOT,28 intubation 
will be performed if at least one of the following criteria 
is fulfilled: neurological failure defined as agitation or 
altered consciousness defined as a Glasgow coma scale 
below 12 points, haemodynamic failure defined as the 
need for a dose of norepinephrine >0.3 µg/kg/min of 
norepinephrine-equivalent to maintain systolic blood 
pressure >90 mm Hg, persisting or worsening respiratory 
failure defined by the presence of at least two criteria 
among the following: respiratory rate >40/min, lack of 
improvement of high respiratory muscle workload, severe 
hypoxemia defined as a need for FiO2 of 100% to main-
tain SpO2 ≥92% or PaO2/FiO2 ≤100 mm Hg, and acidosis 
defined as pH <7.35 units.
outcomes
Primary outcome
The primary outcome is mortality at day 28 after 
randomisation.
Secondary outcomes
Secondary outcome variables include the following:
1. Mortality in ICU, in hospital, at day 90 and at day 180.
2. Intubation at day 28 from randomisation.
3. Length of stay in ICU and in hospital.
4. Number of ventilator-free days, and number of oxygen-
ation techniques-free days within the 28 days following 
randomisation.
5. Tolerance of oxygenation techniques.
sample size
We determined that inclusion of 280 analysable patients 
would provide a power of 80% to highlight an absolute 
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Figure 2 Flowchart of timing in collection of different variables. FiO2, fraction of inspired oxygen; HFOT, high-flow nasal 
oxygen therapy; ICU, intensive care unit; NIV, non-invasive ventilation; PaO2, PaO2 of arterial oxygen; PaCO2, PaO2 of arterial 
carbon dioxide; SpO2, peripheral capillary oxygen saturation.
difference of 15% in rate of mortality at day 28 after rando-
misation between the control group using HFOT with 
NIV (mortality rate estimated of 35%) and the interven-
tion group using HFOT alone (mortality rate estimated 
of 20%). As NIV may be more effective according to type 
of immunosuppression, stratification will be performed 
in order to have the same number of patients with haema-
tological malignancy, leucopenia or neutropenia induced 
by chemotherapy in each group.
Estimated rates of mortality in the two groups
The estimated mortality rates in the two groups are 
based on the recent literature. Mortality rates at day 
28 reported in patients treated with HFOT and NIV 
are particularly homogeneous: 37% in a retrospective 
monocentre study,13 38% in a post hoc analysis of a 
randomised trial10 and 36% in our preliminary study.11 A 
lower mortality rate (24%) has been reported in patients 
treated with NIV in a randomised trial.6 However, this 
difference could be explained by the lower severity 
of respiratory failure at admission. According to our 
previous studies, we can estimate a mortality rate of 20% 
in the interventional group.10 11 A recent trial reported 
a mortality rate of 36% in patients treated with HFOT 
alone.29 However, a high proportion of patients died 
without prior intubation in the HFOT alone group (55 
patients, 40%), that is, with a do-not-intubate order, and 
the actual mortality rate was closer to 25% after exclu-
sion of these patients.
recruitment
Initial expected duration of patient inclusion is 2 years, 
starting in January 2017.
1. End of 2015: grant award;
2. 2016: approval by an independent ethics committee.
3. 2017: inclusion of patients.
4. 2019: end of inclusions, monitoring of participating 
centres and queries to investigators; overseeing by the 
steering committee at the REVA Network meetings; 
blind review to determine protocol violation, to define 
intention-to-treat and per-protocol analysis popula-
tions; new queries to investigators, cleaning and clo-
sure of the database.
5. 2020–2021: data analysis, writing of the manuscript 
and submission for publication.
MEthods: AssIgnEMEnt of IntErvEntIon, dAtA 
CollECtIon, MAnAgEMEnt And AnAlysIs
Allocation and sequence intervention
A computer-generated randomisation is performed 
with stratification according to centre and the type of 
immunosuppression (haematological malignancy or 
leucopenia <1 G/L or neutropenia ≤0.5 G/L vs the 
other types of immunosuppression) in a 1:1 ratio and 
by blocks, using a centralised web-based management 
system (Clinfile). After randomisation, the strategy 
assigned to the patient (HFOT alone or with NIV) will 
be initiated immediately.
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data collection and management
Data will be collected on an electronic-Case Report 
Form (e-CRF) by a trained investigator or research assis-
tant at each centre (figure 2). At time of inclusion, the 
following data will be collected: informed consent, demo-
graphic characteristics, Charlson score,28 vital signs, 
current oxygenation settings (oxygen flow under stan-
dard oxygen, FiO2 and gas flow under HFOT, and FiO2, 
PS levels and PEEP under NIV), tolerance to oxygenation 
devices using a visual analogue scale, arterial blood gases 
and analysis of chest X-ray. Similar data and an evaluation 
of dyspnoea using a 5-point Likert scale will be recorded 
at H1, between H6 and H12, at H24 ±6 hours, H48 ±6 
hours and H72 ±6 hours after randomisation. Duration 
of the first NIV session and total duration of NIV within 
the first 24 hours, between H24 and H48 and between 
H48 and H72 will be collected to ensure adherence to 
the protocol. The type of ventilator used for NIV and 
the NIV interface will be noted. For intubated patients, 
time and reason for intubation will be documented 
according to the above-mentioned criteria. Invasive venti-
latory settings, arterial blood gases and chest X-ray will be 
recorded during the first 3 days following intubation. At 
day 28, vital status, need for intubation, total duration of 
invasive ventilation and of each oxygenation technique 
studied will be recorded. At ICU and hospital discharge, 
vital status and length of stay will be noted. At day 90 and 
day 180, vital status and Eastern Cooperative Oncology 
Group score will be recorded.30
As the absence of aetiology of acute respiratory failure 
could influence mortality,31 investigators are strongly 
encouraged to have an active diagnostic strategy. Results 
of the non-invasive diagnostic tests, bronchoalveolar 
lavage and chest CT-scan will be collected.32
statistical methods
All the analyses will be performed by the study statisti-
cian according to a predefined statistical analysis plan 
and using statistical software (SAS V.9.4). A two-tailed p 
value of <0.05 will be considered as indicating statistical 
significance.
Descriptive analysis of patient groups at baseline
Continuous variables will be summarised with the classic 
parameters of descriptive analysis (median and inter-
quartile ranges or mean and standard deviation), while 
indicating the number of missing data. Category vari-
ables will be presented in the form of absolute frequency 
and percentage in each modality. The analysis will be 
performed on an intention-to-treat basis, including 
all patients having undergone randomisation. Devia-
tions from the protocol will be described and analysed 
on a case-by-case basis after validation by a blind review 
committee.
No imputation for missing values will be carried out.
Analysis pertaining to the main criteria of evaluation
Mortality rates at day 28 after randomisation will be 
compared between the two groups by means of a χ2 test. 
Analysis of this primary outcome will subsequently be 
completed by multivariate logistic regression after testing 
for interactions between treatment effect and strata. 
Survival time will be described by means of Kaplan-Meier 
method and compared with a log-rank test at day 28. A 
Cox proportional-hazards model will be used to calculate 
hazard ratio with 95% confidence interval.
Logistic and Cox regression maximal models will 
include all the variables associated with mortality at day 
28 with a p value <0.20 in the univariate analysis. The final 
model will be obtained by a backward-selection proce-
dure and will include variables significantly associated 
with mortality at day 28 with a p value of <0.05.
Analysis pertaining to the secondary criteria of evaluation
Length of stay, number of ventilator-free days and number 
of oxygenation technique-free days will be compared 
between the two treatment groups using the Student’s 
t-test (or Mann-Whitney test if necessary). Time to ICU 
death, time to hospital death or time to intubation will 
be described by means of the Kaplan-Meier method 
and compared between the two treatment groups with a 
log-rank test. Efficacy and tolerance of oxygenation tech-
niques will be compared between the two groups using 
Student’s t-test (or Mann-Whitney test) for quantitative 
variables and χ2 test for qualitative variables. Ventila-
tor-free days at day 28 will be calculated as one point for 
each day between inclusion to day 28 that patients are 
both alive and free of mechanical ventilation.
Per-protocol analysis
The proportion of patients treated according to the 
prespecified intervention goals will be calculated for each 
randomisation group. According to their sample size, 
their outcomes will be compared using the same methods 
as in the intention-to-treat analysis.
Predetermined subgroup analysis
Randomisation is stratified according to type of immu-
nosuppression in order to have the same number of 
patients with haematological malignancy, leucopenia or 
neutropenia induced by chemotherapy in each group. 
A subgroup analysis will consequently be performed for 
the main and secondary criteria of evaluation in this 
subgroup of patients and in patients with another type of 
immunosuppression. Prior to adjustment, an interaction 
test will be carried out to detect heterogeneity of treat-
ment effect according to type of immunosuppression.
As benefits of HFOT may be influenced by baseline 
PaO2/FiO2, a subgroup analysis will be performed for the 
main and secondary criteria of evaluation in patients with 
PaO2/FiO2≤200 mm Hg at inclusion.
Subgroup analysis will be performed according to:
1. The cause of respiratory failure as it may influence 
outcomes.31
2. The type of NIV interface in the control group as it 
may influence outcomes.33
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3. The existence of protocol violations during the first 48 
hours after inclusion.
Ancillary study
Data on nutrition practice in patients with acute respira-
tory failure is scarce.34 In voluntary participating centres, 
we have planned to collect nutrition practice. Therefore, 
in an ancillary study, we will describe daily nutritional 
intake from inclusion to day 28 or intubation or ICU 
discharge or death, type of nutrition, amount of calories 
intake, existence of complications related to nutrition 
and the reason for maintaining patient fasting.
Data monitoring
An investigator at each centre will be responsible for 
daily patient screening, enrolling patients in the study, 
ensuring adherence to the protocol and completing the 
e-CRF. Research assistants will regularly monitor all the 
centres on site to check adherence to the protocol and 
accuracy of the data recorded.
Patient and public involvement
Patients and public were not involved in the study
study status
1. Current status: the last patient was included on 4 
March 2019.
2. Expected date of complete data collection: mid-Sep-
tember 2019 (6-month follow-up of the last patient in-
cluded).
3. Expected date of the end of monitoring of participat-
ing centres: December 2019.
4. Expected starting date of data analysis: first trimester 
2020.
EthICs And dIssEMInAtIon
Consent or assent
Patients will be included after verification of the eligibility 
criteria and having provided an informed consent to the 
investigator according to the decision of the central ethics 
committee. For patients not able to provide informed 
consent, their next-of-kin will be contacted according to 
the same procedure. Patients will be informed as soon as 
possible by the investigator of their participation in the 
study and their consent to continue to participate in the 
study will be retrieved.
Confidentiality
Data will be handled according to French law. All orig-
inal records will be archived at trial sites for 25 years. The 
clean database file will be deidentified and kept for 25 
years.
declaration of interest
The FLORALI-IM study is an investigator-initiated trial 
supported by the French Ministry of Health with funds 
obtained in 2015 from an inter-regional hospital clin-
ical research programme (‘Programme Hospitalier 
de Recherche Clinique Inter-Régional 2015’). The 
European research network REVA has endorsed the 
study project. The study is promoted by the University 
Hospital of Poitiers. The study promoter has received a 
grant from AADAIRC and Le Nouveau Souffle. Fisher 
& Paykel Healthcare provides high-flow oxygen therapy 
equipment and face masks for NIV to all the participating 
centres but has no other involvement in the study.
Access to data
All investigators will have access to the final data set. 
Participant-level data sets will be made accessible on a 
controlled access basis.
dissemination policy
Findings will be published in peer-reviewed journals and 
presented at local, national and international meetings 
and conferences to publicise and explain the research to 
clinicians, commissioners and service users.
dIsCussIon
In immunocompromised patients, invasive ventilation is 
associated with particularly high mortality rates and appli-
cation of NIV is currently recommended as a means of 
avoiding intubation.5 Almost 20 years ago, two randomised 
controlled trials including a small sample of patients 
reported decreased intubation and mortality rates with 
NIV as compared with standard oxygen therapy.7 8 By 
contrast, more recent studies including larger samples of 
patients have found either similar outcomes or even an 
increased risk of mortality in patients treated with NIV 
compared with oxygen alone.6 10 In a large controlled trial 
including 376 immunocompromised patients, outcomes 
were similar between patients treated with NIV and those 
treated with oxygen therapy.6 However, a high propor-
tion of patients had mild respiratory failure, more than 
one-third of the patients in the control group received 
HFOT while those in the interventional group received 
short sessions of NIV, and all these factors together may 
have mitigated the difference between the two groups.6 
In a post hoc analysis of a randomised controlled trial 
including 82 immunocompromised patients with severe 
acute hypoxemic respiratory failure, patients treated with 
HFOT alone had lower mortality than those treated with 
HFOT with NIV sessions.10
To explain the lack of effect or harmful effects of NIV, it 
could be argued that NIV was not carried out with optimal 
ventilator settings for patients of whom the majority met 
the clinical criteria for ARDS. Indeed, they had partic-
ularly large tidal volumes under NIV, which could be 
associated with increased risk of mortality by potential 
worsening of pre-existing lung injury.15–17 35 36 PEEP levels 
remained relatively low whereas the treatment represents 
a major adjustment in ARDS patients, and NIV was applied 
for a duration of only 8 hours in mean within the first 24 
hours.6 10 Another study has found that NIV performed 
with helmet may be more efficient than with face mask.33 
Interestingly, patients treated with helmet also received 
8 Coudroy R, et al. BMJ Open 2019;9:e029798. doi:10.1136/bmjopen-2019-029798
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lower PS levels and higher PEEP levels than those treated 
with facemask, thereby highlighting the potential impact 
of ventilatory settings on outcomes.33 Consequently, we 
decided to apply a protective NIV protocol aiming at 
avoiding large tidal volumes, and applying prolonged 
sessions of NIV with high PEEP levels.
In a recent large randomised controlled trial including 
776 immunocompromised patients, mortality rates at day 
28 did not differ between patients treated with HFOT and 
those treated with standard oxygen.29 However, 40% of 
the deceased patients in the HFOT group died without 
prior intubation and the high proportion of patients with 
do-not-intubate order may have mitigated the benefi-
cial effects of HFOT.29 By contrast, several studies have 
reported promising results of HFOT alone versus stan-
dard oxygen or NIV in patients with de novo respiratory 
failure, even in immunocompromised patients.10–12 14
The FLORALI-IM trial has several strengths. First, it will 
be the first study comparing HFOT alone versus HFOT 
with NIV sessions in immunocompromised patients. 
Second, the study will include only patients with severe 
acute hypoxemic respiratory failure. Third, NIV will be 
optimised using low levels of PS targeting a tidal volume 
between 6 and 8 mL/kg, PEEP levels of at least 8 cm H2O 
and duration of NIV >12 hours a day during the first 48 
hours.
In conclusion, the FLORALI-IM trial is an investiga-
tor-initiated randomised controlled trial empowered to 
test the hypothesis that HFOT alone may in comparison 
with HFOT and NIV decrease mortality rate at day 28 of 
immunocompromised patients admitted to ICU for acute 
respiratory failure. Innovative aspects include the two 
groups of treatment in this clinical setting and the opti-
mised protocol to carry out NIV and HFOT.
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